Last reviewed · How we verify
Fentanyl citrate; Naltrexone; Naloxone — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Fentanyl citrate; Naltrexone; Naloxone (Fentanyl citrate; Naltrexone; Naloxone) — Alza Corporation, DE, USA.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fentanyl citrate; Naltrexone; Naloxone TARGET | Fentanyl citrate; Naltrexone; Naloxone | Alza Corporation, DE, USA | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fentanyl citrate; Naltrexone; Naloxone CI watch — RSS
- Fentanyl citrate; Naltrexone; Naloxone CI watch — Atom
- Fentanyl citrate; Naltrexone; Naloxone CI watch — JSON
- Fentanyl citrate; Naltrexone; Naloxone alone — RSS
Cite this brief
Drug Landscape (2026). Fentanyl citrate; Naltrexone; Naloxone — Competitive Intelligence Brief. https://druglandscape.com/ci/fentanyl-citrate-naltrexone-naloxone. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab